Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 LAMEA Live Biotherapeutic Products And Microbiome CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 LAMEA C.difficile Market by Country
3.2 LAMEA Crohns Disease Market by Country
3.3 LAMEA IBS Market by Country
3.4 LAMEA Diabetes Market by Country
3.5 LAMEA Others Market by Country
Chapter 4. LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 Brazil Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 Argentina Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 Argentina Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 UAE Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 UAE Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 Saudi Arabia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.5 South Africa Live Biotherapeutic Products And Microbiome CDMO Market
4.5.1 South Africa Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.6 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market
4.6.1 Nigeria Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.7 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market
4.7.1 Rest of LAMEA Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
Unique Offerings 